72922-60-2

Usage

Uses

Used in Organic Synthesis:
Methyl3-aMino-4-Methyl-5-nitrobenzoate is used as a chemical intermediate for various organic synthesis reactions. Its distinct functional groups allow for a wide range of chemical transformations, making it a versatile compound in the field of chemistry.
Used in Pharmaceutical Industry:
Methyl3-aMino-4-Methyl-5-nitrobenzoate is used as a building block in the synthesis of pharmaceutical compounds. Its unique structure and functional groups can be utilized to create new drug molecules with potential therapeutic applications.
Used in Chemical Research:
Methyl3-aMino-4-Methyl-5-nitrobenzoate is used as a research compound in the study of chemical reactions and properties. Its distinct functional groups provide opportunities for exploring new reaction pathways and understanding the behavior of different chemical groups in various contexts.
Note: The specific applications and uses of Methyl3-aMino-4-Methyl-5-nitrobenzoate may be subject to proprietary research or specific applications in the field of chemistry, as detailed information regarding its reaction characteristics and properties is not broadly available.

Upstream product

• 49592-71-4 methyl 4-methyl-3,5-dinitrobenzoate 
• 16533-71-4 3,5-dinitro-p-toluic acid 

Downstream Products

• 1057652-84-2 methyl 3-chloro-4-methyl-5-nitrobenzoate 
• 1057652-89-7 Methyl 3-fluoro-4-methyl-5-nitro-benzoate 
• 1070887-37-4 C₁₁H₁₃NO₅ 
• 1070887-44-3 C₁₂H₁₅NO₅ 
• 1057652-85-3 methyl 4-bromomethyl-3-chloro-5-nitro-benzoate 
• 1070886-76-8 C₂₀H₂₆ClNO₈ 
• 1070886-77-9 C₁₁H₁₀ClNO₆ 
• 1070886-78-0 C₁₇H₁₄Cl₂N₂O₅ 
• 1070886-79-1 C₁₇H₁₆Cl₂N₂O₃ 
• 1070885-59-4 C₂₇H₂₈Cl₂N₄O₄S 
• 1070886-45-1 C₁₂H₁₀ClNO₈ 
• 1070886-33-7 C₂₆H₂₆Cl₂N₄O₄S 
• 54591-64-9 3-hydroxy-4-methyl-5-nitrobenzoic acid 
• 33713-02-9 3-methoxy-4-methyl-5-nitrobenzoic acid methyl ester 

Relevant academic research and scientific papers

EZH2 INHIBITOR AND PHARMACEUTICALLY ACCEPTABLE SALTS AND POLYMORPHIC SUBSTANCES THEREOF, AND APPLICATION OF EZH2 INHIBITOR

The present invention provides an EZH2 inhibitor and pharmaceutically acceptable salts and polymorphic substances thereof, and application of the EZH2 inhibitor. Specifically, the present invention provides N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)m

X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson’s Disease

Human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan 2,3-dioxygenase (hTDO) have been closely linked to the pathogenesis of Parkinson’s disease (PD); nevertheless, development of dual hIDO1 and hTDO inhibitors to evaluate their potential efficacy against PD is still lacking. Here, we report biochemical, biophysical, and computational analyses revealing that 1H-indazole-4-amines inhibit both hIDO1 and hTDO by a mechanism involving direct coordination with the heme ferrous and ferric states. Crystal structure-guided optimization led to23, which manifested IC50values of 0.64 and 0.04 μM to hIDO1 and hTDO, respectively, and had good pharmacokinetic properties and brain penetration in mice.23showed efficacy against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse motor coordination deficits, comparable to Madopar, an anti-PD medicine. Further studies revealed that different from Madopar,23likely has specific anti-PD mechanisms involving lowering IDO1 expression, alleviating dopaminergic neurodegeneration, reducing inflammatory cytokines and quinolinic acid in mouse brain, and increasing kynurenic acid in mouse blood.

TYK2 INHIBITORS AND USES THEREOF

Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

4,5,6-TRI-SUBSTITUTED INDAZOLES DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN MEDICINES

Provided are 4,5,6-tri-substituted indazoles derivatives, a preparation method therefor, and a use thereof in medicines. Specifically, provided are compounds of formula (I) or pharmaceutically acceptable salts, stereoisomers, solvates, or prodrugs thereof

Orally active zwitterionic factor Xa inhibitors with long duration of action

We have optimized 2-aminomethylphenylamine derivative as a factor Xa inhibitor. Several polar functional groups were introduced in the central phenyl ring, and we focused on zwitter ionic compound showing continuous inhibitory activity in oral administrat

Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics

Inhibition of the aspartyl protease BACE-1 has the potential to deliver a disease-modifying therapy for Alzheimer's disease. We have recently disclosed a series of transition-state mimetic BACE-1 inhibitors showing nanomolar potency in cell-based assays.

HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE

The present invention relates to novel hydroxyethylamine compounds of formula (I): (I) having Asp2 (-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated-amyloid levels or-amyloid deposits, particularly Alzheimer's disease.